Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 12

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 12
---
. At this meeting, three nominees for director are to be elected as Class I directors for a three-year term expiring at our 2028 annual meeting of stockholders and until their successors are duly elected and qualified. The nominees, who were recommended for nomination by the nominating and corporate governance committee of our board of directors, are Matthew K. Fust, R. Scott Struthers, Ph.D., and Rogério Vivaldi Coelho, M.D. The Class II directors have one year remaining on their terms of office and the Class III directors have two years remaining on their terms of office. If no contrary indication is made, proxies in the accompanying form are to be voted for Mr. Fust, Dr. Struthers, and Dr. Vivaldi, or in the event that any of Mr. Fust, Dr. Struthers, or Dr. Vivaldi is not a candidate or is unable to serve as a director at the time of the election (which is not currently expected), for any nominee who is designated by our board of directors to fill the vacancy. Each of Mr. Fust, Dr. Struthers, and Dr. Vivaldi is currently a member of our board of directors. All of our directors bring to the board of directors’ significant leadership experience derived from their professional experience and service as executives or board members of other corporations and/or private equity and venture capital firms. The process undertaken by the nominating and corporate governance committee in recommending qualified director candidates is described below under “Board Diversity and Director Nomination Process.” Certain individual qualifications and skills of our directors that contribute to the board of directors’ effectiveness as a whole are described in the following paragraphs. Information Regarding Directors The information set forth below as to the directors and nominees for director has been furnished to us by the directors and nominees for director: Nominees for Election to the Board of Directors For a Three-Year Term Expiring at the 2028 Annual Meeting of Stockholders (Class I)

| Name                         |     | Age |     | Present Position with Crinetics Pharmaceuticals, Inc. |
| R. Scott Struthers, Ph.D.    |     |  63 |     | President, Chief Executive Officer and Director       |
| Matthew K. Fust              |     |  60 |     | Director                                              |
| Rogério Vivaldi Coelho, M.D. |     |  61 |     | Director                                              |

R. Scott Struthers, Ph.D .